Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310336326> ?p ?o ?g. }
- W4310336326 endingPage "822" @default.
- W4310336326 startingPage "811" @default.
- W4310336326 abstract "The Helping to End Addiction Long-termSM Initiative supports a wide range of programs to develop new or improved prevention and opioid addiction treatment strategies. An essential component of this effort is to accelerate development of non-opioid pain therapeutics. In all fields of medicine, therapeutics development is an arduous process and late-stage translational efforts such as clinical trials to validate targets are particularly complex and costly. While there are plentiful novel targets for pain treatment, successful clinical validation is rare. It is therefore crucial to develop processes whereby therapeutic targets can be reasonably 'de-risked' prior to substantial late-stage validation efforts. Such rigorous validation of novel therapeutic targets in the preclinical space will give potential private sector partners the confidence to pursue clinical validation of promising therapeutic concepts and compounds.In 2020, the National Institutes of Health (NIH) held the Target Validation for Non-Addictive Therapeutics Development for Pain workshop to gather insights from key opinion leaders in academia, industry, and venture-financing.The result was a roadmap for pain target validation focusing on three modalities: 1) human evidence; 2) assay development invitro; 3) assay development invivo." @default.
- W4310336326 created "2022-12-08" @default.
- W4310336326 creator A5000644127 @default.
- W4310336326 creator A5001783135 @default.
- W4310336326 creator A5006056386 @default.
- W4310336326 creator A5012734930 @default.
- W4310336326 creator A5013019154 @default.
- W4310336326 creator A5020276346 @default.
- W4310336326 creator A5020505455 @default.
- W4310336326 creator A5028315849 @default.
- W4310336326 creator A5029958480 @default.
- W4310336326 creator A5031219597 @default.
- W4310336326 creator A5046681721 @default.
- W4310336326 creator A5051209585 @default.
- W4310336326 creator A5056987748 @default.
- W4310336326 creator A5059149721 @default.
- W4310336326 creator A5064089644 @default.
- W4310336326 creator A5065208828 @default.
- W4310336326 creator A5069949159 @default.
- W4310336326 creator A5070926507 @default.
- W4310336326 creator A5076974332 @default.
- W4310336326 creator A5077964300 @default.
- W4310336326 creator A5083411013 @default.
- W4310336326 creator A5086670531 @default.
- W4310336326 creator A5089354059 @default.
- W4310336326 date "2022-09-02" @default.
- W4310336326 modified "2023-10-06" @default.
- W4310336326 title "Preclinical target validation for non-addictive therapeutics development for pain" @default.
- W4310336326 cites W1567917561 @default.
- W4310336326 cites W1583390202 @default.
- W4310336326 cites W1864822730 @default.
- W4310336326 cites W1964384832 @default.
- W4310336326 cites W1977612793 @default.
- W4310336326 cites W1987647071 @default.
- W4310336326 cites W1987777080 @default.
- W4310336326 cites W2005733093 @default.
- W4310336326 cites W2014454039 @default.
- W4310336326 cites W2018459912 @default.
- W4310336326 cites W2021159598 @default.
- W4310336326 cites W2022319223 @default.
- W4310336326 cites W2037615805 @default.
- W4310336326 cites W2041635174 @default.
- W4310336326 cites W2047849079 @default.
- W4310336326 cites W2067833766 @default.
- W4310336326 cites W2075525691 @default.
- W4310336326 cites W2079730145 @default.
- W4310336326 cites W2082704080 @default.
- W4310336326 cites W2089410147 @default.
- W4310336326 cites W2090380471 @default.
- W4310336326 cites W2109296561 @default.
- W4310336326 cites W2114072069 @default.
- W4310336326 cites W2123785702 @default.
- W4310336326 cites W213693423 @default.
- W4310336326 cites W2137516955 @default.
- W4310336326 cites W2137598081 @default.
- W4310336326 cites W2142777743 @default.
- W4310336326 cites W2157253302 @default.
- W4310336326 cites W2161860257 @default.
- W4310336326 cites W2164207648 @default.
- W4310336326 cites W2286444762 @default.
- W4310336326 cites W2319861779 @default.
- W4310336326 cites W2464049161 @default.
- W4310336326 cites W2468940127 @default.
- W4310336326 cites W2511664426 @default.
- W4310336326 cites W2520219328 @default.
- W4310336326 cites W2552402939 @default.
- W4310336326 cites W2616243096 @default.
- W4310336326 cites W2762851710 @default.
- W4310336326 cites W2771466141 @default.
- W4310336326 cites W2781615726 @default.
- W4310336326 cites W2782428259 @default.
- W4310336326 cites W2799993759 @default.
- W4310336326 cites W2808146399 @default.
- W4310336326 cites W2891660975 @default.
- W4310336326 cites W2892601996 @default.
- W4310336326 cites W2902845309 @default.
- W4310336326 cites W2910147056 @default.
- W4310336326 cites W2910729187 @default.
- W4310336326 cites W2921726292 @default.
- W4310336326 cites W2924650435 @default.
- W4310336326 cites W2937633935 @default.
- W4310336326 cites W2944311729 @default.
- W4310336326 cites W2949289016 @default.
- W4310336326 cites W2950652380 @default.
- W4310336326 cites W2954870473 @default.
- W4310336326 cites W2956614119 @default.
- W4310336326 cites W2966318597 @default.
- W4310336326 cites W2966928045 @default.
- W4310336326 cites W2995245946 @default.
- W4310336326 cites W3023985995 @default.
- W4310336326 cites W3035623431 @default.
- W4310336326 cites W3086622481 @default.
- W4310336326 cites W3095897671 @default.
- W4310336326 cites W3098598581 @default.
- W4310336326 cites W3099179819 @default.
- W4310336326 cites W3099426215 @default.
- W4310336326 cites W3121822561 @default.
- W4310336326 cites W3157431283 @default.